From BioHealth Investor
Biotechnology
BIONOVO INC [BNVI.OB] +24.42%
IOMAI CORPORATION [IOMI] +15.29%
GENITOPE CORPORATION [GTOP] +13.17%
ARTES MEDICAL, INC. [ARTE] +10.93%
MICROMET INC [MITI] +10.04%
Diagnostic Substances
SYNOVA HEALTHCARE GR [SNVH.OB] +12.00%
HEALTHCARE TECH LTD [HCTL] +4.94%
NYMOX PHARM CORP [NYMX] +3.52%
COLEY PHARMACEUTICAL [COLY] +2.46%
ASPENBIO PHARMA INC [APNB.OB] +2.46%
Drug Delivery
EMISPHERE TECH [EMIS] +8.19%
SKYEPHARMA PLC [SKYE] +6.04%
NOVADEL PHARMA INC [NVD] +5.26%
IOMED INC [IOX] +5.08%
INSITE VISION INC [ISV] +2.01%
Drug Manufacturers
PLANET TECHS INC [PLNT.OB] +23.97%
JAVELIN PHARMACEUTIC [JAV] +6.06%
ANGIOTECH PHARMA I [ANPI] +5.47%
NOVOGEN LTD ADS [NVGN] +5.09%
MARSHALL EDWARDS [MSHL] +5.00%
Medical Appliances & Equipment
ZOLL MEDICAL CP [ZOLL] +11.47%
CELSION CORP [CLN] +5.66%
SIGNALIFE INC [SGN] +5.33%
SHAMIR OPTICAL INDUS [SHMR] +4.61%
VNUS MEDICAL TECHNOL [VNUS] +4.51%
Medical Instruments & Supplies
UROPLASTY INC [UPI] +10.17%
EP MEDSYSTEMS INC [EPMD] +8.18%
ROCHESTER MEDICAL [ROCM] +7.98%
IMPLANT SCIENCES CP [IMX] +7.88%
CARDIAC SCIENCE CORP [CSCX] +6.58%
Medical Laboratories & Research
RADNET INC [RDNT.OB] +4.14%
BIO-REFERENCE LAB [BRLI] +2.06%
BIOFORCE NANOSCIENCE [BFNH.OB] +1.16%
PHARM PROD DEV [PPDI] +0.86%
AETERNA ZENTARIS [AEZS] +0.69%
http://www.biohealthinvestor.com/
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.